Comparison of four digoxin immunoassays with respect to interference from digoxin-like immunoreactive factors

Abstract

Objectives: Comparison of a new monoclonal digoxin assay with three polyclonal digoxin assays for their cross-reactivity to digoxinlike immunoreactive factors (DLIF) and digoxin metabolites. Design and Methods: Sixty-:six nondigitalized patient samples from 5 different groups: neonates, women in 3rd trimester pregnancy, and patients with liver or renal diseases, or undergoing organ transplants, and 139 samples from digoxin-treated patients of 4 categories (hospital sick, liver, renal, and outpatients) were compared in 4 different digoxin assays: (a) ACS™ Digoxin (ACS) developed for the automated chemiluminescent Ciba Corning ACS 180 ® system, (b) Baxter Stratus™ (Stratus, a fluoroimmunoassay), (c) Ciba-Corning Magic TM (Magic, a radioimmunoassay), and (d) an in-house radioimmunoassay (RIA). The ACS TM and RIA were also compared for their cross-reactivity to four principal digoxin metabolites. Results and Conclusion: Among the nondigitalized specimens, no significant DLIF interference was found for all 4 assays among the pregnant women or liver and transplant patients. However, the neonates registered high DLIF interference with Magic™ and RIA, but none for ACS™ or Stratus™. DLIF interference in renal samples was highest in the Magic assay and lowest in RIA. Among the specimens with digoxin, a higher number of discrepant samples were found from the sick patients than from outpatients. In 75% of such discrepant samples, the ACS™ result was less than other assay results, suggesting DLIF as the probable cause. The two assays differed most in their cross-reactivity to the deglycated metabolites, digoxigenin and its mono-digitoxoside.